2012 Controversies in Neuroscience Session

March 2, 2012

Share:

Wednesday, April 25, 2012
2:00 p.m. – 5:00 p.m.

Moderators: Joseph Jankovic, MD, FAAN and Walter Rocca, MD, MPH

Join 10 experts in their fields as they discuss five of today's most controversial topics in neuroscience. Using the debate format, two speakers will take questions and answers—and challenge each other's knowledge.

2:00 p.m. – 2:30 p.m.
CSF and Alzheimer's Disease Biomarkers

Side 1: Biomarkers for AD:  Ready for Prime Time? Ronald Petersen, MD, PhD

Side 2: Aβ biomarkers (Aβ42 in CSF and Aβ imaging with PET scanning) should be used clinically to diagnose persons with mild cognitive impairment at risk for dementia due to Alzheimer's Disease, and for research in cognitively normal persons. Niklas Mattsson, MD, PhD

2:30 p.m. – 3:00 p.m.
Behavioral Therapy in Autistic Patients

Side 1: Benefits of facilitated communication in patients with autism TBD

Side 2: Risks of facilitated communication in patients with autism Max Wiznitzer, MD, FAAN

3:00 p.m. – 3:30 p.m.
Diaphragm Pacing for ALS (Pacer Study)

Side 1: Treatment and interpretation of the findings of this study (Pro) Raymond Onders, MD

Side 2: Treatment and interpretation of the findings of this study (Con) Catherine Lomen-Hoerth, MD, PhD

3:30 p.m. – 3:45 p.m.
Break


3:45 p.m. – 4:15 p.m.
How much adult neurology training does a child neurologist need?

Side 1: Increasing the length of required child neurology training (and reducing adult neurology training) for child neurologists Donald Gilbert, MD, FAAN

Side 2: Maintaining the current length of required adult neurology training for child neurologists Douglas Larsen, MD, M.Ed.

4:15 p.m. – 4:45 p.m.
Surgery versus Stenting (CREST Trial)

Side 1: How do you think the clinical trial evidence should affect the decision to refer patients for an endovascular procedure vs. endarterectomy in the major patient subgroups TBD

Side 2: The potential influence that new data from aggressively medically managed patients raises questions in the asymptomatic carotid case James Meschia, MD, FAAN

4:45 p.m. – 5:00 p.m.
Closing remarks